作者: Moon H. Nahm , Sandra Romero-Steiner
DOI: 10.1128/9781555815820.CH15
关键词:
摘要: This chapter reviews opsonophagocytosis assay (OPA) methods for pneumococcal antibodies and the experience with OPA in clinical trials, stressing need further standardization of OPA. In case conjugate vaccines (PCV), studies suggest that vaccine-induced primarily help phagocytes ingest kill pneumococci. mechanism host protection is described this chapter. Given essential defense against pneumococci, are designed to induce opsonic antibodies. The describes two different types clinically available various laboratory measures were used estimate their protective efficacy. PCV becomes T cell dependent, induces B-cell memory, can elicit anti-polysaccharide (PS) young children. most desirable surrogate measuring immunity. uses a historical approach describe methods. However, classical very tedious perform, due counting colonies. Consequently, many researchers have developed alternative requiring no colony counting, including radiolabeled-bacterium uptake assay, fluorescent-bacterium chemiluminescence, an oxidative-burst generation assay. Clinical measured opsonophagocytic antibody activity children adults. Due past methodological difficulties, these tended be small size. They nevertheless informative thus discusses Finally, finally talks about future activities will likely become basis evaluating efficacy protein vaccines.